These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 20851366)

  • 1. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
    Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
    Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
    Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
    Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists.
    Chaturvedi P; Pai PS; Chaukar DA; Gupta S; D'cruz AK
    Eur J Surg Oncol; 2010 Jun; 36(6):541-5. PubMed ID: 20071132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonates-associated osteonecrosis of the jaw: review on reported cases].
    Gering A; Grange L; Villier C; Woeller A; Mallaret M
    Therapie; 2007; 62(1):49-54. PubMed ID: 17374348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 15. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
    Lee J
    J Infus Nurs; 2009; 32(6):330-5. PubMed ID: 19918142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings.
    Krishnan A; Arslanoglu A; Yildirm N; Silbergleit R; Aygun N
    J Comput Assist Tomogr; 2009; 33(2):298-304. PubMed ID: 19346864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.
    Bagan J; Scully C; Sabater V; Jimenez Y
    Oral Oncol; 2009 Jul; 45(7):551-4. PubMed ID: 19251474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
    Junquera L; Gallego L
    J Oral Maxillofac Surg; 2008 Jul; 66(7):1516-7. PubMed ID: 18571043
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.